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Abstract
Gonadotropin-releasing hormone analogues (GnRHa) are recommended as initial treatment for adolescents diagnosed with 
gender dysphoria, providing time to follow gender identity development and consider further treatment wishes without distress 
caused by unwanted pubertal changes. This has been described as an extended diagnostic phase. However, there are also con-
cerns about the physical, neurocognitive, and psychosocial effects of this treatment. In this retrospective study, we document 
trajectories after the initiation of GnRHa and explore reasons for extended use and discontinuation of GnRHa. Treatment 
was considered appropriate in 143 (67%) of the 214 adolescents eligible for GnRHa treatment by virtue of their age/pubertal 
status, and all started GnRHa (38 transgirls, 105 transboys; median age, 15.0 years [range, 11.1–18.6] and 16.1 years [range, 
10.1–17.9]). After a median duration of 0.8 years (0.3–3.8) on GnRHa, 125 (87%) started gender-affirming hormones (GAH). 
Nine (6%) discontinued GnRHa, five of whom no longer wished gender-affirming treatment. Thirteen had used GnRHa for 
longer than required by protocol for reasons other than logistics and regularly met with a mental health professional during 
this time, supporting the use of GnRHa treatment as an extended diagnostic phase. In conclusion, the vast majority who started 
GnRHa proceeded to GAH, possibly due to eligibility criteria that select those highly likely to pursue further gender-affirming 
treatment. Due to the observational character of the study, it is not possible to say if GnRHa treatment itself influenced the 
outcome. Few individuals discontinued GnRHa, and only 3.5% no longer wished gender-affirming treatment.
Keywords Gender dysphoria · Transgender · Gonadotropin-releasing hormone analogues · Hormone treatment · Gender 
identity
Introduction
Increasing numbers of young people diagnosed with gender 
dysphoria are seen by pediatric endocrinologists. Gender 
dysphoria is the persistent feeling of incongruence between 
gender identity (sense of being a man, woman, or other) and 
the sex assigned at birth. The diagnosis gender dysphoria can 
be made if the Diagnostic and Statistical Manual of Mental 
Disorders (DSM-5) criteria are met (American Psychiatric 
Association, 2013). The prevalence of gender dysphoria 
among Dutch adolescents aged 12–18 years was recently 
estimated to be 1 in 6300 based on numbers of adolescents 
seeking medical treatment, with a ratio of transboys (assigned 
female at birth) to transgirls (assigned male at birth) of 1.9:1 
(Wiepjes et al., 2018). Genetic, hormonal, psychological, and 
social factors may play a role, but the exact etiology of gender 
dysphoria remains unknown (de Vries & Cohen-Kettenis, 
2012; Hembree et al., 2017; Martinerie et al., 2018).
Gender dysphoria in prepubertal children can be expressed 
by dislike of their physical sex characteristics and gender 
incongruent behavior. In many children, gender dysphoria 
will not persist, but if the gender dysphoric feelings intensify 
during puberty, they are thought to be unlikely to subside (de 
Vries & Cohen-Kettenis, 2012; Hembree et al., 2017; Zucker 
et al., 2011). When puberty starts (Tanner genital/breast stage 
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2) and gender dysphoria persists, adolescents are eligible to 
start with puberty suppression using gonadotropin-releasing 
hormone analogues (GnRHa) (Coleman et al., 2011; Hem-
bree et al., 2017). GnRHa treatment aims to give the adoles-
cent the opportunity to explore their gender identity and time 
to consider if they wish to pursue gender-affirming treatment 
while development of unwanted secondary sex characteris-
tics is suppressed in order to reduce distress (Hembree et al., 
2017; Zucker et al., 2011). Effects of GnRHa on pubertal 
development are reversible. This is in contrast to gender-
affirming hormones which have largely irreversible effects on 
secondary sex characteristics and may compromise fertility 
after prolonged use (De Roo, Tilleman, T’Sjoen, & De Sutter, 
2016; Hembree et al., 2017).
Short-term adverse effects of GnRHa are hot flushes at the 
start of the treatment and sometimes mood alterations and 
fatigue (Delemarre-van de Waal & Cohen-Kettenis, 2006; 
Hembree et al., 2017; Schagen, Cohen-Kettenis, Delemarre-
van de Waal, & Hannema, 2016). Few data are available 
on long-term adverse effects. Bone mineral density may be 
affected (Klink, Caris, Heijboer, van, & Rotteveel, 2015; Vlot 
et al., 2017), and since puberty is an important period for 
brain development (Sisk & Zehr, 2005), puberty suppres-
sion with GnRHa might also influence brain development. 
There is a lack of studies investigating effects of GnRHa on 
the brain. One study examined executive function and con-
cluded that GnRHa treatment had no detrimental effects on 
performance (Staphorsius et al., 2015). However, a longitu-
dinal study among 25 adopted girls treated with GnRHa for 
early puberty reported a decrease in IQ from 100.2 ± 12.7 to 
93.1 ± 10.5 with a significant decline of performance score 
during treatment, but it was concluded that the decrease in 
IQ was not clinically relevant (Mul et al., 2001). A limitation 
of the study was the lack of a control group. A second small 
cross-sectional study of girls treated with GnRHa because of 
precocious puberty found no significant difference in cogni-
tive functioning, behavioral, and social problems compared 
to healthy age-matched controls, but the study did not have 
enough power to detect differences smaller than one standard 
deviation (Wojniusz et al., 2016). Wojniusz et al. did report 
that emotional reactivity was possibly higher in girls treated 
with GnRHa although these results were not conclusive. Girls 
with early or precocious puberty are treated at a younger age 
so it is unclear to what extent these results apply to adolescents 
treated with GnRHa for gender dysphoria. Further studies are 
needed to assess if and what effects GnRHa have on various 
aspects of brain development in adolescence.
Opinions about the use of GnRHa vary (Vrouenraets, Fre-
driks, Hannema, Cohen-Kettenis, & de Vries, 2015). Argu-
ments for the use of GnRHa that have been brought forward 
are the benefit of early treatment with GnRHa for mental 
health and quality of life (de Vries, Steensma, Doreleijers, & 
Cohen-Kettenis, 2011). Furthermore, it gives the adolescent 
and treatment team more time to explore the adolescent’s 
gender identity and treatment wishes (Hembree et al., 2017). 
If the adolescent pursues gender-affirming treatment, some 
surgeries may not be necessary or less invasive as secondary 
sex characteristics are less developed. Early treatment is cor-
related with better postsurgical outcomes, possibly because 
of a physical appearance more in line with the affirmed gen-
der (Cohen-Kettenis & van Goozen, 1997; Leibowitz & de 
Vries, 2016). However, this may not be of equal importance 
to all adolescents and early puberty suppression also pre-
cludes certain surgeries such as penile inversion vaginoplasty 
by limiting penile growth. Some have argued that puberty-
blocking treatment prevents devastating psychological and 
physical harms including suicide and that adolescents should 
therefore be able to access this treatment even without paren-
tal approval (Dembroff, 2019; Priest, 2019), but others have 
underscored that there is no evidence that puberty suppres-
sion prevents suicide and that the risk of suicide, although 
high, should not be overstated and should be seen in compari-
son with a clinical comparison group rather than the general 
population (Antommaria, Shapiro, & Conard, 2019; Baker, 
2019; Zucker, 2019).
Arguments against the use of GnRHa that have been raised 
include possible long-term adverse effects on health, psycho-
logical, and sexual functioning (Laidlaw, Cretella, & Dono-
van, 2019; Richards, Maxwell, & McCune, 2019; Vrouenraets 
et al., 2015). Some state that adolescents may be unable to 
make far-reaching decisions at a young age, especially in the 
presence of comorbid psychiatric conditions, which are com-
mon among youth with gender dysphoria (Korte et al., 2008; 
Laidlaw et al., 2019; Vrouenraets et al., 2015). Furthermore, 
gender identity develops and may change during adolescence. 
Concerns have been raised that the use of GnRHa may influ-
ence this process and might increase the likelihood of persis-
tence of gender dysphoria (Korte et al., 2008; Laidlaw et al., 
2019; Richards et al., 2019; Stein, 2012; Vrouenraets et al., 
2015). It is unknown if the use of GnRHa prevents resolution 
of gender dysphoria (Korte et al., 2008). Many prepubertal 
children with gender dysphoria no longer experience gender 
dysphoria in adolescence, and the experience of romantic and 
sexual attraction is thought to play an important role in this pro-
cess (Steensma, Biemond, de Boer, & Cohen-Kettenis, 2011). 
Some may come to understand themselves as homosexual or 
bisexual (Steensma et al., 2011). GnRHa, by blocking sexual 
development, might interfere with this process (Korte et al., 
2008). Another concern is that although GnRHa treatment is 
to be used as an extended diagnostic phase, the start of it may 
lead the adolescents and parents to assume that transgender 
outcome is the only possible outcome which may prevent 
exploration of other possibilities (Leibowitz & de Vries, 2016).
To gain more insight into the use of GnRHa in adolescents 
with gender dysphoria, the current study aims to document 
trajectories after the initiation of GnRHa, i.e., discontinuation 
Archives of Sexual Behavior 
1 3
of GnRHa, prolonged use of GnRHa, and initiation of gender-
affirming hormones; to investigate the duration of GnRHa 
treatment; and to explore reasons for extended use and dis-
continuation of GnRHa.
Method
Participants
This is a single-center retrospective study. Out of 269 chil-
dren and adolescents registered at the Curium-Leiden Uni-
versity Medical Centre gender clinic in Leiden, the Neth-
erlands, 214 were pubertal and within the appropriate age 
range for treatment at our pediatric clinic. Out of these, 143 
(67%) had started GnRHa treatment between November 2010 
(when the clinic first started) and January 1, 2018. The study 
population consisted of these 143 adolescents (38 transgirls, 
105 transboys). Not included in the study were children and 
adolescents in whom gender dysphoria was not diagnosed 
(n = 39), those who had coexisting problems that interfered 
with the diagnostic process and/or might interfere with suc-
cessful treatment (n = 9), those that did not wish hormonal 
treatment (n = 4), those in whom the diagnostic evaluation 
was still ongoing (n = 10), and those who had stopped to 
attend appointments (n = 9).
Of adolescents who had started GnRHa, treatment status 
as of 1 July 2019 was reviewed. If they had used GnRHa 
monotherapy for more than 3 months longer than minimally 
required before the start of gender-affirming hormones 
according to the local protocol (see below for description of 
the treatment protocol), the reason for this was noted. The 
3 months was chosen to select those who may have had a 
prolonged diagnostic phase rather than those in whom gen-
der-affirming hormone therapy started slightly later due to 
logistical issues such as rescheduling of an appointment. 
Adolescents who had started GnRHa treatment and had 
stopped this treatment were included in a detailed review. 
Baseline characteristics such as age and gender and data on 
the start, duration, and discontinuation of treatment were 
recorded from the medical files, as well as reasons given for 
the discontinuation of GnRHa treatment and the adolescents’ 
and parents’ views on the treatment.
Procedure
Before the start of GnRHa treatment, all adolescents had a diag-
nostic evaluation by a pediatric endocrinologist and mental 
health professional (MHP) to confirm the diagnosis of gender 
dysphoria according to the DSM-5 criteria (American Psychi-
atric Association, 2013), to assess the presence of any medi-
cal, psychiatric, or psychosocial problems that might interfere 
with treatment, to assess if the adolescent was able to give 
informed consent for the treatment and to confirm that puberty 
had started, as recommended by current guidelines (Hembree 
et al., 2017). This evaluation usually consisted of approximately 
six visits (more if necessary) of the adolescent with an MHP 
in 6–12 months in addition to interviews with parents/guard-
ians. All adolescents gave written informed consent for the 
treatment. Informed consent from parents/guardians was also 
required if the adolescent was < 16 years old. After the start of 
GnRHa treatment, follow-up visits were scheduled with the 
pediatric endocrinologist and MHP, usually every 3 months in 
the first year and every 3–6 months thereafter, to evaluate sat-
isfaction with the treatment, adequacy of puberty suppression, 
and any side effects. In the case of mental health issues (psy-
chiatric morbidity but also issues such as difficulty to express 
oneself and doubts about one’s gender identity), adolescents 
were either seen more frequently by the psychologist of the 
gender team or referred to a local MHP for therapy.
According to the local protocol, adolescents were eligi-
ble for gender-affirming hormone treatment from the age of 
16 years and after at least 6 months of GnRHa treatment. No 
maximum time of use of GnRHa was defined in the protocol. 
From 2016, adolescents who had already been treated with 
GnRHa for at least 3 years were eligible for gender-affirming 
hormone treatment from the age of 15 years. From 2017, 
those who had been treated with GnRHa for at least 2 years 
and were 15 years old were eligible. Before the start of gen-
der-affirming hormones, evaluation by a MHP and pediatric 
endocrinologist took place to assess the indication, any con-
traindications, and ability to give informed consent for this 
treatment. If adolescents had discontinued GnRHa treatment, 
there was a follow-up appointment at which adolescents and 
parents were asked about current feelings regarding gender 
identity and how they looked back on the treatment.
Results
During the study period, 143 adolescents started GnRHa treat-
ment (38 transgirls, 105 transboys). Median age at the start 
of treatment was 15.0 years (range, 11.1–18.6 years) in trans-
girls and 16.1 years (range, 10.1–17.9 years) in transboys. Of 
these adolescents, 125 (87%, 36 transgirls, 89 transboys) sub-
sequently started treatment with gender-affirming hormones 
after 1.0 (0.5–3.8) and 0.8 (0.3–3.7) years of GnRHa treatment 
(see Fig. 1). Median age at the start of gender-affirming hor-
mones was 16.2 years (range, 14.5–18.6 years) in transgirls 
and 17.1 years (range, 14.9–18.8 years) in transboys. Five ado-
lescents who used GnRHa had not started gender-affirming 
hormones at the time of data collection, because they were not 
yet eligible for this treatment due to their age. At the time of 
data collection, they had used GnRHa for a median duration 
of 2.1 years (1.6–2.8). Six adolescents had been referred to a 
gender clinic elsewhere for further treatment. One of these was 
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17 years old and eligible for gender-affirming hormones but 
initially indicated he needed more time to decide about testos-
terone treatment and subsequently stated that he wished to delay 
the start of this treatment until after his school examinations. 
The other five were not eligible yet due to their age at the time of 
referral. Nine had discontinued GnRHa treatment (see below), 
one of whom restarted GnRHa after 5 months. This individual 
and two others subsequently started gender-affirming hormone 
treatment (Fig. 1).
Prolonged Use of GnRHa
Twenty adolescents (3 transgirls and 17 transboys) had used 
GnRHa for longer than minimally required by protocol. One 
was the transboy mentioned above who needed more time 
to decide about testosterone treatment. He had used GnRHa 
for 2.5 years when he was referred from the pediatric clinic 
to a clinic for adults elsewhere. The other 19 adolescents 
had subsequently started gender-affirming hormones. The 
median duration of GnRHa monotherapy in these 19 adoles-
cents was 1.0 year (0.8–2.4). Reasons for prolonged use of 
GnRHa were (sometimes there was more than one reason): 
unstable situation due to family issues such as lack of paren-
tal support and/or acceptance of gender dysphoria (n = 6) 
or social problems such as lack of a safe home, excessive 
school absenteeism (n = 5); (psychiatric) comorbidity (n = 8) 
such as autism or depression; more time needed for decision 
about gender-affirming hormone treatment by the adolescent 
(n = 1) or for further diagnostics by the gender team (n = 1, 
because of non-binary aspects); and logistic issues such as 
missed/rescheduled appointments (n = 8; in 7 this was the 
only reason). The 11 adolescents who received prolonged 
GnRHa treatment because of mental health and/or psycho-
social problems had regular (approximately monthly on aver-
age) appointments with a psychologist at the gender clinic 
(n = 5) and/or received support from a local MHP (n = 9) 
during this period.
Discontinuation of GnRHa Treatment
From the 143 adolescents who started GnRHa treatment, nine 
(6%; one transgirl, eight transboys) stopped this treatment 
after a median duration of 0.8 years (0.1–3.0), at a median 
age of 15.0 years (13.4–18.9). Four individuals discontinued 
although they did wish further endocrine treatment because 
of gender dysphoria. One stopped treatment because of an 
increase in mood problems and suicidal thoughts and confu-
sion attributed to GnRHa treatment and restarted treatment 
(gender-affirming hormone treatment) at an adult gender 
clinic elsewhere. He later indicated: “I was already fully 
matured when I started GnRHa, menstruations were already 
suppressed by contraceptives. For me, it had no added value” 
(transboy, age 19 years).
Another transboy experienced hot flushes, an increase in 
migraine, and had fear of injections in addition to stress due 
to problems at school and unrelated medical issues and there-
fore wished to temporarily discontinue GnRHa treatment 
after 4 months. He restarted 5 months later and subsequently 
started testosterone treatment. A third transboy experienced 
mood swings starting 4 months after he had begun GnRHa 
treatment. A year later, he started to frequently feel unwell 
and miss school. After 2.2 years, he developed severe nau-
sea and rapid weight loss for which no cause was identified. 
Because of this deterioration of his general condition, he 
wished to discontinue GnRHa treatment after 2.4 years. He 
gradually recovered over the next 2 years. He subsequently 
started lynestrenol and testosterone treatment. The last ado-
lescent had stopped GnRHa because his parents were unable 
to regularly collect medication from the pharmacy and take 
him to appointments for the injections. He subsequently 
started lynestrenol to suppress menses; he is not eligible yet 
for testosterone treatment.
The five others (3.5%) no longer wished gender-affirming 
treatment. One adolescent had been very distressed about 
breast development at the start of GnRHa. She later thought 
Fig. 1  Flow chart showing 
the trajectories of adolescents 
who started GnRH analogue 
(GnRHa) treatment. GAH 
gender-affirming hormone 
treatment
n=143 Started GnRHa 
Stopped GnRHa
Too young to start GAH
Referred to elsewhere
Prolonged GnRHa
n=125 Start GAH
Continued GnRHa
n=1 Start GAH at adult gender clinic
n=5 No wish for gender 
affirming treatment
105  19
1 restarted
134 9 
5 
1 
5 1 
20 
1 
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that she might want to live as a woman without breasts. She 
did not want to live as a boy and did not wish testosterone 
treatment and decided to discontinue GnRHa although she 
dreaded breast development and menstruation. Another ado-
lescent had concurrent psychosocial problems interfering 
with the exploration of gender identity and did not currently 
wish treatment. When looking back on GnRHa treatment this 
individual said: “The decision to stop GnRHa to my mind 
was made by the gender team, because they did not think 
gender dysphoria was the right diagnosis. I do still feel like a 
man, but for me it is okay to be just me instead of a he or a she, 
so for now I do not want any further treatment” (adolescent 
assigned female sex at birth, age 16 years).
One adolescent felt more in between man and woman and 
therefore did not wish to continue treatment: “At the moment, 
I feel more like ‘I am’ instead of ‘I am a woman’ or ‘I am a 
man’” (adolescent assigned female sex at birth, age 16 years).
Another individual made a social transition while using 
GnRHa and shortly afterward decided to discontinue treat-
ment. He indicated that he had fallen in love with a girl and 
had never had such feelings, which made him question his 
gender identity. At subsequent visits, he indicated that he was 
happy living as a man.
The last adolescent stated: “After using GnRHa for the first 
time, I could feel who I was without the female hormones, 
this gave me peace of mind to think about my future. It was 
an inner feeling that said I am a woman” (adolescent assigned 
female sex at birth, age 18 years).
The adolescents and parents were also asked about their 
views on GnRHa in the treatment protocol for gender dys-
phoria. All of them saw it as the first step in treatment, but 
it was also clear that it was used as an extended diagnostic 
phase. They all felt free to stop GnRHa. They had varying 
visions on the role of GnRHa in the treatment of gender dys-
phoria. Some stated it gave them time to think and feel who 
they were and what they wanted in the future and felt that 
without GnRHa treatment they would not have been able to 
make these decisions. Others stated that GnRHa should not 
be routinely offered before the start of gender-affirming hor-
mones when adolescents are already fully matured, because 
of the lack of physical benefits. Instead, a consideration time 
of 6 months with psychological follow-up was suggested.
Discussion
The great majority of adolescents who started GnRHa sub-
sequently started gender-affirming hormones as soon as 
they were eligible for this treatment. Very few discontinued 
treatment, although slightly more than in previous studies in 
which cohorts of transgender adolescents were described. 
Out of 333 adolescents that had started puberty suppres-
sion at the VUmc gender clinic in the Netherlands up until 
December 2015, 1.9% stopped; reasons for discontinuation 
of GnRHa were not reported (Wiepjes et al., 2018). In the 
Canadian study by Khatchadourian, Amed, and Metzger 
(2014), one of 27 individuals who started GnRHa stopped 
the treatment due to emotional lability, not because the wish 
to pursue transition had subsided. In the current study, 6% of 
those who started GnRHa discontinued and 3.5% no longer 
wished gender-affirming treatment.
Several studies reviewed by Ristori and Steensma (2016) 
have found that much higher percentages (61–98%) of prepu-
bertal children no longer experience gender dysphoria (“desist”) 
as adolescents. The period between 10 and 13 years seems to be 
a crucial period in which social changes (for example starting 
secondary school), the physical changes of puberty, and first 
romantic and sexual experiences may lead to either an increase 
or a decrease/resolution of gender dysphoria (Steensma et al., 
2011). The adolescents that start GnRHa treatment have entered 
puberty and are mostly older than 13 years and may be past this 
critical period so that gender dysphoria may be more likely to 
persist. This may explain the lower percentage of resolution of 
gender dysphoria found in the studies of treated adolescents. In 
addition, the groups that started treatment in previous studies 
and in the current study consisted of selected adolescents that 
had had an extensive diagnostic process to establish if they met 
the eligibility criteria for treatment as well as the diagnostic 
criteria for gender dysphoria (Wiepjes et al., 2018). Alterna-
tively, concerns have been raised that GnRHa treatment itself 
may increase the chances of persistence of gender dysphoria 
(Korte et al., 2008; Richards et al., 2019; Stein, 2012; Vrouen-
raets et al., 2015). Whether or not GnRHa treatment influenced 
gender identity development cannot be concluded from the cur-
rent study due to its observational nature. The study does show 
that gender identity development was not suppressed in all, as 
a few adolescents discontinued GnRHa because they no longer 
experienced gender dysphoria, but it is unknown if gender dys-
phoria would have subsided in more adolescents in the absence 
of GnRHa treatment.
For one adolescent, the experience of falling in love made 
him doubt whether he was transgender. This is in line with 
previous findings that the first romantic experiences and the 
awareness of one’s sexual attraction play an important role in 
the resolution of gender dysphoria in adolescents (Steensma 
et al., 2011). This emphasizes the importance of this topic in 
the diagnostic evaluation. However, some adolescents may 
not have had any romantic or sexual experiences, especially 
if they present at an early age. In addition, transgender ado-
lescents were shown to be less experienced, both sexually and 
romantically, compared to peers from the general population 
(Bungener, Steensma, Cohen-Kettenis, & de Vries, 2017). 
GnRHa treatment prevents the physical changes of puberty 
and is known to negatively affect sexual desire (Plosker & 
Brogden, 1994). Puberty suppression might thus decrease 
the chances of adolescents having romantic and sexual 
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experiences which might in turn influence gender identity 
development (Korte et al., 2008). This was not true for the 
adolescent in the current study who fell in love while using 
GnRHa and then decided to discontinue treatment, but it is 
uncertain if more adolescents would have had such experi-
ences if they had not used GnRHa.
Two individuals who discontinued GnRHa indicated that 
they did not feel either male or female. A non-binary gender 
identity appears to be becoming more common among ado-
lescents presenting at gender clinics (Butler, De Graaf, Wren, 
& Carmichael, 2018). For these adolescents, it may be more 
difficult to find out and understand their own gender identity 
and it is unclear what constitutes optimal care for this group.
Experienced side effects played a role in the decision to 
discontinue GnRHa treatment in three adolescents. However, 
for none of the adolescents who stopped GnRHa in the cur-
rent study, were potential long-term side effects a reason to 
decline or discontinue GnRHa treatment. Lack of information 
about long-term effects of GnRHa use was not considered an 
important problem by interviewed adolescents with gender 
dysphoria in the study by Vrouenraets, Fredriks, Hannema, 
Cohen-Kettenis, and de Vries (2016), but is seen as a major 
problem by many professionals (Vrouenraets et al., 2015).
In the current study, 13 adolescents who were eligible 
for gender-affirming hormone treatment used GnRHa mono-
therapy for longer than the minimum time required by pro-
tocol for reasons other than logistics. During this time, they 
received mental health support from a local MHP or from a 
psychologist from the gender team. This supports the idea 
that the time on GnRHa is used as an extended diagnostic 
phase where the adolescents can further explore their gender 
identity and treatment wishes and work on issues that might 
interfere with successful treatment. The great majority started 
gender-affirming hormones as soon as was possible within 
the treatment protocol, after a median duration of approxi-
mately one year. This does not mean that for them this time 
was not used as an extended diagnostic phase. Those who 
were youngest at the start of GnRHa were treated the longest, 
up to 3.8 years, with visits to the clinic every 3–6 months. In 
this period of growing up, becoming more independent, and 
discovering oneself, their development was followed by the 
team and discussed in relation to the treatment. Older ado-
lescents, who presented after age 16 years, were often treated 
with GnRHa for the minimum period of 6 months. Generally, 
they were more mature than the younger adolescents at the 
start of the diagnostic process and many already had clear 
ideas about their treatment wishes. In adults, gender-affirm-
ing hormones are usually started directly after the diagnostic 
phase (Wiepjes et al., 2018).
The period of puberty suppression used in adolescents is 
considered worthwhile by some of the adolescents, as the 
individual in the current study who indicated it gave peace 
of mind to think about the future. On the other hand, some 
postpubertal adolescents perceived little benefit of the treat-
ment, as stated by one transboy who discontinued GnRHa 
in the current study. A possible benefit of GnRHa treatment 
for fully matured transgender boys may be the suppression 
of menstrual bleeding. Alternative methods may be used to 
achieve this, although GnRHa are more effective than pro-
gestins to immediately and fully suppress menstruation (Tack 
et al., 2016). Furthermore, many adolescents do not wish to 
use continuous oral contraceptives because of the fact that 
they contain “female” hormones and because of fear that 
breast size may increase. Adolescents should be counseled 
on all available treatment options and their (side) effects so 
that they can make an informed choice.
The relatively small size of the cohort that was described 
is a limitation of the current study as well as its retrospective 
character. The duration of follow-up was limited, and in some 
of the adolescents who stopped GnRHa treatment because 
they no longer experienced gender dysphoria, gender dyspho-
ria might recur later in life. The observational design does not 
allow conclusions about any possible effect of GnRHa treat-
ment on gender identity development. A randomized con-
trolled trial in adolescents presenting with gender dysphoria, 
comparing groups with and without GnRHa treatment, could 
theoretically shed light on the effect of GnRHa treatment on 
gender identity development. However, many would con-
sider a trial where the control group is withheld treatment 
unethical, as the treatment has been used since the nineties 
and outcome studies although limited have been positive (de 
Vries et al., 2014; Smith, van Goozen, & Cohen-Kettenis, 
2001). In addition, it is likely that adolescents will not want 
to participate in such a trial if this means they will not receive 
treatment that is available at other centers. Mul et al. (2001) 
experienced this problem and were unable to include a con-
trol group in their study on GnRHa treatment in adopted girls 
with early puberty because all that were randomized to the 
control group refused further participation. An alternative 
approach that has been suggested to gain more insight into 
the effect of treatment on gender identity development is to 
collect baseline data at the time of referral from adolescents 
who are on a long waiting list for diagnostic evaluation and 
treatment and compare the percentage of these adolescents in 
whom gender dysphoria is still present after a certain period 
of time to that in adolescents on GnRHa treatment (Zucker, 
2019).
In conclusion, this study shows that a small number of 
adolescents discontinued GnRHa treatment because they no 
longer wished gender-affirming treatment. This indicates 
that not all adolescents and parents assume that transgender 
outcome is the only possible outcome and shows that gen-
der identity can still fluctuate when using GnRHa, at least 
in some adolescents. However, gender dysphoria subsided 
in a small number of adolescents and it is uncertain if this 
would have been different without GnRHa treatment. Some 
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adolescents used GnRHa for a prolonged period before start-
ing gender-affirming hormones while regularly meeting with 
an MHP which is consistent with the use of GnRHa treat-
ment as an extended diagnostic phase. The great majority 
who had started GnRHa treatment continued with gender-
affirming hormones. It is important to take this into account 
when counseling adolescents who consider this treatment 
and their parents.
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